Skip to Main Content

U.S. Court in Maryland Says Drug Maker Reasonably Interpreted Medicaid Rebate Statute, Dismisses Whistleblower Action

  • November 20, 2020

A qui tam relator could not plausibly allege that Forest Laboratories (Forest), a subsidiary of Allergan plc, made false statements with the requisite knowledge to violate the False Claims Act (FCA) because its interpretation of ambiguous Medicaid Drug Rebate Program requirements was objectively reasonable, a federal court in Maryland held recently.

You must be logged in to access this content.